#METABOLOMICS WORKBENCH Jung_DNLI_20250922_144939 DATATRACK_ID:6472 STUDY_ID:ST004287 ANALYSIS_ID:AN007128 PROJECT_ID:PR002323 VERSION 1 CREATED_ON October 14, 2025, 11:39 am #PROJECT PR:PROJECT_TITLE PILRA regulates microglial neuroinflammation and lipid metabolism as a candidate PR:PROJECT_TITLE therapeutic target for Alzheimer’s disease PR:PROJECT_TYPE Cellular studies PR:PROJECT_SUMMARY The Alzheimer’s disease (AD) human genetic landscape identified microglia as a PR:PROJECT_SUMMARY key disease-modifying brain cell type. A common loss-of-function coding variant PR:PROJECT_SUMMARY in paired immunoglobulin-like type 2 receptor alpha (PILRA) associated with PR:PROJECT_SUMMARY reduced AD risk, was found enriched in a cohort of healthy centenarians and PR:PROJECT_SUMMARY rescued APOE4 AD risk. However, the mechanisms underlying protection are PR:PROJECT_SUMMARY undefined. Here we identify biological functions of PILRA, an immunoreceptor PR:PROJECT_SUMMARY tyrosine-based inhibitory motif (ITIM)-containing receptor, in human PR:PROJECT_SUMMARY iPSC-derived microglia (iMG) and chimeric AD mice. CRISPR-mediated PILRA PR:PROJECT_SUMMARY knockout (KO) in iMG rescued ApoE4-induced immunometabolic deficits. Moreover, PR:PROJECT_SUMMARY loss of PILRA confers a signature of metabolic resilience in microglia with PR:PROJECT_SUMMARY increased mitochondrial capacity in tandem with elevated antioxidants, reduced PR:PROJECT_SUMMARY ROS and toxic lipid species. Additionally, PILRA KO iMG exhibit improved PR:PROJECT_SUMMARY lysosomal degradation, enhanced migration, and attenuated cytokine responses. We PR:PROJECT_SUMMARY show PPAR and STAT1/3 act as master regulators that mediate downstream signaling PR:PROJECT_SUMMARY and regulate PILRA-dependent microglial functions. Importantly, AD mice PR:PROJECT_SUMMARY transplanted with human PILRA KO microglia showed reduced amyloid pathology and PR:PROJECT_SUMMARY rescued levels of synaptic markers. Finally, we identify a high-affinity human PR:PROJECT_SUMMARY PILRA-specific antagonist antibody that phenocopies PILRA KO. Together, these PR:PROJECT_SUMMARY findings suggest a therapeutic approach to modulate microglial immunometabolism PR:PROJECT_SUMMARY by inhibiting PILRA, thus identifying a pharmacologically tractable target for PR:PROJECT_SUMMARY AD. PR:INSTITUTE Denali Therapeutics PR:LAST_NAME Suh PR:FIRST_NAME Jung PR:ADDRESS 161 Oyster Point Blvd, South San Francisco, CA 94080 PR:EMAIL suh@dnli.com PR:PHONE +1 6507973837 #STUDY ST:STUDY_TITLE Lipidomic profiling of PILRAKO xMG in xenotransplant model after mouse ST:STUDY_TITLE microglia(mMg) depletion ST:STUDY_SUMMARY To investigate the impact of PILRAKO in healthy and disease contexts, we ST:STUDY_SUMMARY transplanted WT or PILRAKO human microglial progenitors into ST:STUDY_SUMMARY xenotransplantation-compatible hCSF1 and 5x-hCSF1 littermates. 5x-hCSF1 mice, ST:STUDY_SUMMARY which harbor mutant human amyloid precursor protein and presenilin-1 transgenes, ST:STUDY_SUMMARY have previously been shown to develop robust amyloid plaque pathology by 6 ST:STUDY_SUMMARY months of age. To enable CNS-wide replacement of endogenous mouse microglia with ST:STUDY_SUMMARY human microglia, WT and PILRAKO lines were modified to carry a CSF1R-inhibitor ST:STUDY_SUMMARY resistant mutation (CSF1R-G795A)28. At 6.5 months of age, WT or PILRAKO xMG were ST:STUDY_SUMMARY isolated from the brains of hCSF1 and 5x-hCSF1 mice (n=3-4/group). WT xMG ST:STUDY_SUMMARY isolated from 5x-hCSF1 mice exhibited elevated levels of two ST:STUDY_SUMMARY bis(monoacylglycero)phosphate (BMP) lipids, a signature of endo-lysosomal ST:STUDY_SUMMARY dysfunction in which ablation of PILRA rescued BMP accumulation in xMG (Fig 6K). ST:STUDY_SUMMARY These findings are consistent with improved lysosomal function upon PILRA KO. ST:INSTITUTE Denali Therapeutics ST:LAST_NAME Suh ST:FIRST_NAME Jung ST:ADDRESS 161 Oyster Point Blvd, South San Francisco, CA 94080 ST:EMAIL suh@dnli.com ST:PHONE +1 06507973837 #SUBJECT SU:SUBJECT_TYPE Human SU:SUBJECT_SPECIES Homo sapiens SU:TAXONOMY_ID 9606 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data SUBJECT_SAMPLE_FACTORS Pool_1 HSA-000037562 cell_line:NA | disease_state:NA | genotype:NA | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_001; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_001 SUBJECT_SAMPLE_FACTORS 7 HSA-000037085 cell_line:WT | disease_state:5xFAD | genotype:5x-hCSF1 | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_002; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_002 SUBJECT_SAMPLE_FACTORS 14 HSA-000037092 cell_line:PILRAKO | disease_state:5xFAD | genotype:5x-hCSF1 | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_003; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_003 SUBJECT_SAMPLE_FACTORS 13 HSA-000037091 cell_line:PILRAKO | disease_state:5xFAD | genotype:5x-hCSF1 | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_004; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_004 SUBJECT_SAMPLE_FACTORS 11 HSA-000037089 cell_line:PILRAKO | disease_state:WT | genotype:hCSF1 | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_005; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_005 SUBJECT_SAMPLE_FACTORS 8 HSA-000037086 cell_line:WT | disease_state:5xFAD | genotype:5x-hCSF1 | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_006; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_006 SUBJECT_SAMPLE_FACTORS 3 HSA-000037081 cell_line:WT | disease_state:WT | genotype:hCSF1 | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_007; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_007 SUBJECT_SAMPLE_FACTORS 10 HSA-000037088 cell_line:PILRAKO | disease_state:WT | genotype:hCSF1 | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_008; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_008 SUBJECT_SAMPLE_FACTORS 9 HSA-000037087 cell_line:PILRAKO | disease_state:WT | genotype:hCSF1 | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_009; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_009 SUBJECT_SAMPLE_FACTORS Pool_2 HSA-000037563 cell_line:NA | disease_state:NA | genotype:NA | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_010; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_010 SUBJECT_SAMPLE_FACTORS 12 HSA-000037090 cell_line:PILRAKO | disease_state:WT | genotype:hCSF1 | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_011; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_011 SUBJECT_SAMPLE_FACTORS 2 HSA-000037080 cell_line:WT | disease_state:WT | genotype:hCSF1 | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_012; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_012 SUBJECT_SAMPLE_FACTORS 5 HSA-000037083 cell_line:WT | disease_state:5xFAD | genotype:5x-hCSF1 | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_013; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_013 SUBJECT_SAMPLE_FACTORS 6 HSA-000037084 cell_line:WT | disease_state:5xFAD | genotype:5x-hCSF1 | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_014; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_014 SUBJECT_SAMPLE_FACTORS 15 HSA-000037093 cell_line:PILRAKO | disease_state:5xFAD | genotype:5x-hCSF1 | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_015; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_015 SUBJECT_SAMPLE_FACTORS 4 HSA-000037082 cell_line:WT | disease_state:WT | genotype:hCSF1 | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_016; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_016 SUBJECT_SAMPLE_FACTORS 1 HSA-000037079 cell_line:WT | disease_state:WT | genotype:hCSF1 | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_017; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_017 SUBJECT_SAMPLE_FACTORS Pool_3 HSA-000037564 cell_line:NA | disease_state:NA | genotype:NA | Sample source:microglia RAW_FILE_NAME(Raw Source Name.LN)=20240416_TW_HEX-000777_Lipid_Pos_018; RAW_FILE_NAME(Raw Source Name.LP)=20240416_TW_HEX-000777_Lipid_Neg_018 #COLLECTION CO:COLLECTION_SUMMARY Six and half months after HPC transplantation, mice were anesthetized and CO:COLLECTION_SUMMARY intracardially perfused with 1X DPBS, half brains were dissected, the cerebellum CO:COLLECTION_SUMMARY was removed, and tissue was stored in RPMI 1640 until subsequent perfusions were CO:COLLECTION_SUMMARY completed. All steps were performed on ice or at 4°C with ice-cold reagents and CO:COLLECTION_SUMMARY all centrifuge steps were performed for 10 minutes at 400xg with full brake and CO:COLLECTION_SUMMARY acceleration unless otherwise stated. Brains were manually homogenized using a 7 CO:COLLECTION_SUMMARY mL Dounce homogenizer by adding 4 mL of RPMI 1640 and performing 10 strokes with CO:COLLECTION_SUMMARY the “loose” pestle followed by 10 strokes with the “tight” pestle. CO:COLLECTION_SUMMARY Samples were then run through a pre-soaked 70μM filter then the filter was CO:COLLECTION_SUMMARY washed with 10mL of RPMI 1640. The sample was pelleted by centrifugation and CO:COLLECTION_SUMMARY myelin was removed by resuspension in 8 L of 30% Percoll overlaid with 2 mL of CO:COLLECTION_SUMMARY 1X DPBS centrifuged at 400xg for 20 minutes with acceleration set to 0 and brake CO:COLLECTION_SUMMARY set to 4. The myelin band and supernatant were discarded, and cell pellets were CO:COLLECTION_SUMMARY resuspended in 70 μL MACS buffer (0.5% bovine serum albumin in 1X DPBS) + 30 CO:COLLECTION_SUMMARY μL Mouse Cell Removal beads (Miltenyi) and incubated at 4°C for 15 minutes. CO:COLLECTION_SUMMARY Magnetically labeled mouse cells were separated using LS columns and the CO:COLLECTION_SUMMARY MidiMACs separator (Miltenyi) while the unlabeled human cells were collected in CO:COLLECTION_SUMMARY the flow through. Human microglia cells were pelleted, and washed 1x with 0.9% CO:COLLECTION_SUMMARY sodium chloride and collected in Lobind 1.5 mL Eppendorf tubes and snap frozen. CO:SAMPLE_TYPE Microglia CO:STORAGE_CONDITIONS -80℃ CO:COLLECTION_VIALS Lobind 1.5 mL Eppendorf tubes CO:STORAGE_VIALS Lobind 1.5 mL Eppendorf tubes #TREATMENT TR:TREATMENT_SUMMARY No treatment #SAMPLEPREP SP:SAMPLEPREP_SUMMARY On the day of lipid and metabolite extraction, cell pellets were reconstituted SP:SAMPLEPREP_SUMMARY with 400 μL MS grade methanol spiked with internal standards.Samples were SP:SAMPLEPREP_SUMMARY vortexed and volumes were adjusted to 800 μL with MS grade H2O, vortexed again, SP:SAMPLEPREP_SUMMARY then 600 μL tert-butyl methyl ether (MTBE) was added, vortexed, then SP:SAMPLEPREP_SUMMARY centrifuged at 21,000 g for 10 min at 4C. The two phases generated by SP:SAMPLEPREP_SUMMARY centrifugation were separated. Each phase (top: non-polar lipids, bottom: polar SP:SAMPLEPREP_SUMMARY metabolites) was transferred to glass vials and dried overnight using a Genevac SP:SAMPLEPREP_SUMMARY EZ3. Non-polar lipids were resuspended MS grade methanol and polar metabolites SP:SAMPLEPREP_SUMMARY were resuspended in 90% methanol:water mixture. SP:PROCESSING_STORAGE_CONDITIONS On ice SP:EXTRACT_STORAGE -20℃ #CHROMATOGRAPHY CH:CHROMATOGRAPHY_TYPE Reversed phase CH:INSTRUMENT_NAME Agilent 1290 Infinity II CH:COLUMN_NAME Waters ACQUITY UPLC BEH C18 (100 x 2.1mm,1.7um) CH:SOLVENT_A 60% acetonitrile/40% water; 10 mM ammonium acetate; 0.1% acetic acid CH:SOLVENT_B 90% isopropyl alcohol/10% acetonitrile; 10 mM ammonium acetate; 0.1% acetic acid CH:FLOW_GRADIENT 0.0-8.0 min from 45% B to 99% B, 8.0-9.0 min at 99% B, 9.0-9.1 min to 45% B, and CH:FLOW_GRADIENT 9.1-10.0 min at 45% B. CH:FLOW_RATE 0.25 mL/min CH:COLUMN_TEMPERATURE 55°C #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:INSTRUMENT_NAME ABI Sciex 6500+ QTrap MS:INSTRUMENT_TYPE Triple quadrupole MS:MS_TYPE ESI MS:ION_MODE NEGATIVE MS:MS_COMMENTS curtain gas at 30 psi; collision gas set at medium; ion spray voltage at 4,500 MS:MS_COMMENTS V; temperature at 600°C; ion source Gas 1 at 55 psi; ion source Gas 2 at 60 MS:MS_COMMENTS psi. #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS normalized peak area MS_METABOLITE_DATA_START Samples HSA-000037079 HSA-000037080 HSA-000037081 HSA-000037082 HSA-000037083 HSA-000037084 HSA-000037085 HSA-000037086 HSA-000037087 HSA-000037088 HSA-000037089 HSA-000037090 HSA-000037091 HSA-000037092 HSA-000037093 HSA-000037562 HSA-000037563 HSA-000037564 Factors cell_line:WT | disease_state:WT | genotype:hCSF1 | Sample source:microglia cell_line:WT | disease_state:WT | genotype:hCSF1 | Sample source:microglia cell_line:WT | disease_state:WT | genotype:hCSF1 | Sample source:microglia cell_line:WT | disease_state:WT | genotype:hCSF1 | Sample source:microglia cell_line:WT | disease_state:5xFAD | genotype:5x-hCSF1 | Sample source:microglia cell_line:WT | disease_state:5xFAD | genotype:5x-hCSF1 | Sample source:microglia cell_line:WT | disease_state:5xFAD | genotype:5x-hCSF1 | Sample source:microglia cell_line:WT | disease_state:5xFAD | genotype:5x-hCSF1 | Sample source:microglia cell_line:PILRAKO | disease_state:WT | genotype:hCSF1 | Sample source:microglia cell_line:PILRAKO | disease_state:WT | genotype:hCSF1 | Sample source:microglia cell_line:PILRAKO | disease_state:WT | genotype:hCSF1 | Sample source:microglia cell_line:PILRAKO | disease_state:WT | genotype:hCSF1 | Sample source:microglia cell_line:PILRAKO | disease_state:5xFAD | genotype:5x-hCSF1 | Sample source:microglia cell_line:PILRAKO | disease_state:5xFAD | genotype:5x-hCSF1 | Sample source:microglia cell_line:PILRAKO | disease_state:5xFAD | genotype:5x-hCSF1 | Sample source:microglia cell_line:NA | disease_state:NA | genotype:NA | Sample source:microglia cell_line:NA | disease_state:NA | genotype:NA | Sample source:microglia cell_line:NA | disease_state:NA | genotype:NA | Sample source:microglia (3-O-sulfo)GalCer(d18:1/16:0) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. (3-O-sulfo)GalCer(d18:1/18:0(2OH) 0.019 0.078 0.014 0.053 0.007 0.017 0.02 0.352 0.015 0.162 0.041 0.015 0.154 0.038 0.018 0.056 0.074 0.071 (3-O-sulfo)GalCer(d18:1/18:0(d3)) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. (3-O-sulfo)GalCer(d18:1/18:0) 0.028 0.131 0.029 0.054 0.015 0.041 0.042 0.7 0.024 0.203 0.037 0.017 0.305 0.056 0.028 0.097 0.091 0.109 (3-O-sulfo)GalCer(d18:1/24:0(2OH)) 0.071 0.338 0.065 0.214 0.055 0.095 0.111 1.437 0.025 0.485 0.121 0.076 0.704 0.136 0.058 0.229 0.254 0.198 (3-O-sulfo)GalCer(d18:1/24:0) 0.099 0.487 0.067 0.191 0.073 0.103 0.109 1.854 0.053 0.648 0.133 0.093 0.976 0.202 0.071 0.29 0.323 0.246 (3-O-sulfo)GalCer(d18:1/24:1(2OH)) 0.069 0.231 0.049 0.15 0.034 0.072 0.071 1.269 0.029 0.339 0.09 0.029 0.507 0.071 0.034 0.186 0.212 0.183 (3-O-sulfo)GalCer(d18:1/24:1) 0.3 1.874 0.306 0.861 0.164 0.38 0.413 8.002 0.127 2.186 0.488 0.28 3.465 0.636 0.194 1.141 1.109 1.001 Arachidonic acid N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Arachidonic acid-d8 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Arachidonic acid-d8_MRM N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Arachidonic acid_MRM 0.028 0.017 N.D. 0.074 0.018 0.013 0.041 0.02 0.029 N.D. 0.037 0.022 0.033 0.009 0.04 0.027 0.028 0.023 BMP(14:0/14:0) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. BMP(16:0_18:1) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. BMP(16:0_20:4) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. BMP(16:0_22:6) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. BMP(16:1/16:1) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. BMP(18:0_18:1) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. BMP(18:0_20:4) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. BMP(18:0_22:6) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. BMP(18:1/18:1) 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.008 0.001 0.009 0.001 0.001 0.008 0.003 0.001 0.002 0.002 0.002 BMP(20:4/20:4) 0 0.005 N.D. 0.001 0.001 0.002 0.002 0.012 0.001 0.024 0.001 0.002 0.013 0.001 0.001 0.003 0.003 0.004 BMP(22:6/22:6) 0.001 0.004 0.004 0.002 0.003 0.004 0.004 0.009 0.001 0.011 0.003 0.002 0.008 0.002 0.001 0.004 0.004 0.004 CL(14:0/14:0/14:0/14:0) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. CL(72:6/18:2) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. CL(72:7/18:2) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. CL(72:8-2(OOH)/18:2) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. CL(72:8/18:2) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. CL(74:9/18:2) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Cholesterol sulfate 0.75 1.713 1.049 0.35 0.565 1.016 0.57 0.502 0.331 0.447 1.354 1.131 0.571 0.889 0.741 0.739 0.82 0.781 DHA N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. EPA N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. FAHFA(18:1/9-O-18:0) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. GD1a/b(d36:1) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. GD3(d34:1) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. GD3(d36:1) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. GM3(d18:1/18:0(d5)) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. GM3(d34:1) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. GM3(d36:1) N.D. N.D. N.D. N.D. 0.023 0.028 0.043 0.098 N.D. 0.042 N.D. N.D. 0.1 0.051 N.D. N.D. 0.025 0.021 GQ1b(d36:1) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Hemi-BMP(14:0/14:0)_14:0 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Hemi-BMP(18:1/18:1)_16:0 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Hemi-BMP(18:1/18:1)_18:0 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Hemi-BMP(18:1/18:1)_18:1 0 N.D. N.D. N.D. 0 N.D. N.D. N.D. N.D. N.D. 0 N.D. N.D. N.D. N.D. N.D. N.D. N.D. Hemi-BMP(20:4/20:4)_16:0 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Hemi-BMP(20:4/20:4)_18:0 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Hemi-BMP(20:4/20:4)_18:1 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Hemi-BMP(20:4/20:4)_20:4 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Hemi-BMP(22:6/22:6)_16:0 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Hemi-BMP(22:6/22:6)_18:0 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Hemi-BMP(22:6/22:6)_18:1 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Hemi-BMP(22:6/22:6)_22:6 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. LPE(16:0) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. LPE(18:0) 0.007 0.015 0.01 0.021 0.015 0.02 0.025 0.106 0.007 0.025 0.008 0.015 0.068 0.02 0.029 0.022 0.021 0.02 LPE(18:1(d7)) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. LPG(16:0) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. LPG(18:0) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. LPG(18:1) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. LPG(20:4) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. LPG(22:6) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. LPI(16:0) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. LPI(18:0) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Linoleic acid N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Linolenic acid N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Oleic acid 0.949 1.602 1.046 0.649 0.618 0.676 0.488 0.805 0.555 0.943 0.797 0.627 0.666 0.559 0.494 0.721 0.726 0.67 PA(15:0/18:1(d7)) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PA(16:0_18:1) 0.007 0.026 0.006 0.015 0.002 0.003 0.007 0.132 0.006 0.044 0.009 N.D. 0.05 0.006 0.004 0.015 0.011 0.016 PA(18:0_18:1) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PA(18:0_20:4) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PA(18:0_22:6) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PA(18:1/18:1) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PE(15:0/18:1(d7)) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PE(O-16:0/20:4) 0.007 0.047 0.01 0.02 0.005 0.012 0.008 0.112 0.011 0.206 0.01 0.012 0.092 0.01 0.01 0.037 0.033 0.037 PE(O-16:0/22:6) 0.003 0.014 0.004 0.008 0.001 0.004 0.008 0.053 0.003 0.054 0.003 0.006 0.031 0.005 0.006 0.015 0.012 0.017 PE(O-18:0/20:4) 0.007 0.033 0.005 0.012 0.007 0.01 0.013 0.113 0.006 0.143 0.007 0.011 0.085 0.007 0.007 0.034 0.031 0.025 PE(O-18:0/22:6) 0.002 0.009 0.003 0.005 0.002 0.004 0.005 0.04 0.003 0.02 0.003 0.005 0.016 0.006 0.004 0.007 0.007 0.008 PE(P-16:0/20:4) 0.023 0.415 0.039 0.113 0.03 0.063 0.065 0.901 0.054 1.858 0.061 0.093 0.87 0.069 0.064 0.345 0.334 0.35 PE(P-16:0/20:5) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PE(P-16:0/22:4) 0.032 0.174 0.028 0.079 0.029 0.042 0.048 0.643 0.031 0.702 0.032 0.048 0.358 0.051 0.038 0.171 0.166 0.163 PE(P-16:0/22:6) 0.016 0.064 0.017 0.033 0.011 0.018 0.022 0.227 0.014 0.228 0.016 0.021 0.127 0.019 0.022 0.066 0.059 0.077 PE(P-18:0/18:1(d9)) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PE(P-18:0/18:1) 0.137 0.497 0.097 0.233 0.048 0.114 0.134 2.49 0.07 0.677 0.13 0.079 0.91 0.153 0.069 0.352 0.378 0.279 PE(P-18:0/18:2) 0.002 0.007 N.D. 0.004 N.D. N.D. 0.002 0.021 0.003 0.013 0.003 N.D. 0.009 0.002 0.003 0.007 0.005 0.004 PE(P-18:0/20:4) 0.052 0.385 0.056 0.146 0.035 0.077 0.094 1.108 0.062 1.449 0.076 0.105 0.79 0.085 0.05 0.324 0.309 0.274 PE(P-18:0/20:5) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PE(P-18:0/22:6) 0.021 0.049 0.025 0.055 0.013 0.023 0.034 0.303 0.022 0.136 0.029 0.033 0.111 0.031 0.03 0.064 0.066 0.062 PE(P-18:1/20:4) 0.024 0.2 0.03 0.072 0.023 0.035 0.042 0.712 0.032 0.788 0.039 0.046 0.436 0.044 0.035 0.208 0.182 0.198 PE(P-18:1/22:6) 0.006 0.024 0.007 0.018 0.004 0.007 0.008 0.106 0.008 0.066 0.006 0.008 0.038 0.008 0.009 0.029 0.026 0.027 PEth(16:0_18:1) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PEth(18:1/18:1) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PG(15:0/18:1(d7)) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PG(16:0_18:1) 0.003 0.008 0.005 0.007 0.005 0.005 0.005 0.015 0.005 0.022 0.003 0.008 0.015 0.007 0.006 0.008 0.008 0.006 PG(16:0_20:4) 0.001 0 0.001 0.001 0.001 0.001 0.001 0.002 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0 PG(16:0_22:6) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PG(18:0_18:1) 0 0 0.001 0.001 0.001 0.001 0.001 0.003 0.001 0.003 0.001 0.002 0.002 0.001 0.001 0.001 0.001 0.001 PG(18:0_20:4) 0.001 0 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.002 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 PG(18:0_22:6) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PG(18:1/18:1) 0.001 0.001 0.001 0.002 0.001 0.001 0.001 0.002 0.001 0.003 0.001 0.001 0.002 0.001 0.002 0.002 0.002 0.002 PI(15:0/18:1(d7)) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PI(16:0_18:1) N.D. 0.004 0.001 0.003 N.D. 0.001 N.D. 0.011 0.001 0.015 0.002 0.002 0.011 0.001 N.D. 0.004 0.004 0.003 PI(16:0_20:4) 0.004 0.04 0.007 0.015 0.005 0.013 0.009 0.093 0.006 0.142 0.007 0.012 0.082 0.007 0.014 0.021 0.029 0.029 PI(16:0_22:6) N.D. 0.002 N.D. 0.002 N.D. 0.001 0.001 0.006 0.001 0.005 N.D. 0.001 0.003 0.001 0.001 0.002 0.001 0.002 PI(18:0_18:1) N.D. 0.005 0.001 0.002 N.D. 0.003 0.002 0.011 0.001 0.007 N.D. N.D. 0.006 0.001 N.D. 0.004 0.003 0.002 PI(18:0_20:4) 0.022 0.152 0.031 0.068 0.031 0.055 0.051 0.363 0.029 0.503 0.029 0.049 0.351 0.053 0.056 0.108 0.107 0.105 PI(18:0_22:6) 0.001 0.004 0.001 0.004 0.001 0.002 0.003 0.012 0.001 0.016 0.002 0.002 0.011 0.001 0.002 0.004 0.005 0.004 PI(18:1/18:1) 0.001 0.007 0.001 0.002 N.D. 0.001 N.D. 0.013 0.001 0.022 0.001 0.001 0.013 0.002 N.D. 0.003 0.003 0.005 PI(20:4/20:4) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PS(15:0/18:1(d7)) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. PS(16:0_18:1) 0.003 0.026 0.006 0.015 0.003 0.009 0.005 0.084 0.003 0.089 0.006 0.008 0.058 0.009 0.005 0.021 0.022 0.013 PS(16:0_20:4) N.D. 0.01 N.D. N.D. N.D. N.D. N.D. 0.022 N.D. 0.043 N.D. N.D. 0.018 0.005 N.D. 0.008 0.008 0.007 PS(16:0_22:6) N.D. 0.014 N.D. N.D. N.D. N.D. N.D. 0.028 N.D. 0.034 0.004 0.007 0.018 N.D. N.D. 0.01 0.011 N.D. PS(18:0_18:1) 0.051 0.429 0.045 0.158 0.035 0.069 0.075 1.383 0.036 0.946 0.072 0.074 0.794 0.126 0.036 0.229 0.277 0.199 PS(18:0_20:4) 0.015 0.125 0.019 0.044 0.011 0.021 0.029 0.326 0.02 0.394 0.017 0.035 0.236 0.023 0.018 0.081 0.075 0.063 PS(18:0_22:6) 0.129 0.381 0.168 0.35 0.114 0.149 0.251 1.902 0.129 0.795 0.145 0.208 0.803 0.19 0.164 0.408 0.39 0.317 PS(18:1/18:1) 0.017 0.05 0.02 0.043 0.006 0.02 0.021 0.237 0.012 0.131 0.018 0.02 0.105 0.024 0.013 0.046 0.038 0.031 PS(22:6/22:6) N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Palmitic acid 12.573 10.125 12.269 9.664 9.555 9.932 9.436 10.382 9.728 11.309 9.579 9.051 8.871 9.544 8.936 9.512 9.37 9.359 Palmitoleic acid 0.246 2.629 0.328 0.185 0.276 0.305 0.232 0.257 0.151 0.344 1.2 0.373 0.687 0.28 0.215 0.629 0.749 0.599 Stearic acid 0 0.001 0 0 0 0 0 0.001 0 0.001 0.001 0 0 0.001 0.001 0 0 0 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name Expected RT MS1_mz MS2_mz (3-O-sulfo)GalCer(d18:1/16:0) 4.45 778.5 97 (3-O-sulfo)GalCer(d18:1/18:0(2OH) 4.87 822.6 97 (3-O-sulfo)GalCer(d18:1/18:0(d3)) 5.06 809.6 97 (3-O-sulfo)GalCer(d18:1/18:0) 4.96 806.6 97 (3-O-sulfo)GalCer(d18:1/24:0(2OH)) 6.14 906.7 97 (3-O-sulfo)GalCer(d18:1/24:0) 6.19 890.7 97 (3-O-sulfo)GalCer(d18:1/24:1(2OH)) 5.73 904.7 97 (3-O-sulfo)GalCer(d18:1/24:1) 5.79 888.7 97 Arachidonic acid 2.33 303.2 303.2 Arachidonic acid_MRM 2.33 303.2 259.1 Arachidonic acid-d8 2.3 311.3 311.3 Arachidonic acid-d8_MRM 2.3 311.3 267.1 BMP(14:0/14:0) 3.69 665.3 227.2 BMP(16:0_18:1) 4.8 747.5 255.4 BMP(16:0_20:4) 4.13 769.5 255.4 BMP(16:0_22:6) 4.2 795.5 255.4 BMP(16:1/16:1) 3.79 717.5 253.1 BMP(18:0_18:1) 5.25 775.5 281.4 BMP(18:0_20:4) 4.69 797.5 283.4 BMP(18:0_22:6) 4.7 823.5 283.4 BMP(18:1/18:1) 4.84 773.5 281.3 BMP(20:4/20:4) 3.69 817.5 303.3 BMP(22:6/22:6) 3.45 865.5 327.3 Cholesterol sulfate 3.08 465.3 96.7 CL(14:0/14:0/14:0/14:0) 7.17 619.5 227.2 CL(72:6/18:2) 7.48 725.7 279.2 CL(72:7/18:2) 7.24 724.7 279.2 CL(72:8-2(OOH)/18:2) 6.49 755.7 279.2 CL(72:8/18:2) 7.26 723.7 279.3 CL(74:9/18:2) 7.29 736.7 279.2 DHA 2.14 327.2 229.1 EPA 1.97 301.3 257.1 FAHFA(18:1/9-O-18:0) 6.2 563.6 281 GD1a/b(d36:1) 4.54 917.5 290.1 GD3(d34:1) 4.1 720.9 290.1 GD3(d36:1) 4.65 734.9 290.1 GM3(d18:1/18:0(d5)) 5.03 1184.8 290.1 GM3(d34:1) 4.54 1151.7 290.1 GM3(d36:1) 5.05 1179.8 290.1 GQ1b(d36:1) 4.13 1208.6 290.1 Hemi-BMP(14:0/14:0)_14:0 6.2 875.5 227.3 Hemi-BMP(18:1/18:1)_16:0 7.1 1011.7 281.3 Hemi-BMP(18:1/18:1)_18:0 7.2 1039.7 281.3 Hemi-BMP(18:1/18:1)_18:1 7.1 1037.7 281.3 Hemi-BMP(20:4/20:4)_16:0 6.4 1056.8 303.3 Hemi-BMP(20:4/20:4)_18:0 6.6 1185.8 303.3 Hemi-BMP(20:4/20:4)_18:1 6.4 1183.8 303.3 Hemi-BMP(20:4/20:4)_20:4 6.2 1104.8 303.3 Hemi-BMP(22:6/22:6)_16:0 6.2 1103.7 327.3 Hemi-BMP(22:6/22:6)_18:0 6.5 1131.7 327.3 Hemi-BMP(22:6/22:6)_18:1 6.2 1129.7 327.3 Hemi-BMP(22:6/22:6)_22:6 5.6 1175.7 327.3 Linoleic acid 2.46 279.2 279.2 Linolenic acid 2.08 277.2 277.2 LPE(16:0) 1.97 452.2 255.3 LPE(18:0) 2.61 480.3 283.3 LPE(18:1(d7)) 2 485.3 288.3 LPG(16:0) 1.65 483.3 255.3 LPG(18:0) 2.11 511.3 283.3 LPG(18:1) 1.64 509.3 281.3 LPG(20:4) 1.29 531.3 303.3 LPG(22:6) 1.28 555.3 327.3 LPI(16:0) 1.6 571.3 241.1 LPI(18:0) 2.12 599.3 241.1 Oleic acid 2.96 281.2 281.2 PA(15:0/18:1(d7)) 5.09 666.5 241.3 PA(16:0_18:1) 5.45 673.5 255.3 PA(18:0_18:1) 5.84 701.5 283.3 PA(18:0_20:4) 5.42 723.5 283.3 PA(18:0_22:6) 5.35 747.5 283.3 PA(18:1/18:1) 5.36 699.5 281.3 Palmitic acid 2.98 255.1 255.1 Palmitoleic acid 2.35 253.1 253.1 PE(15:0/18:1(d7)) 5.49 709.6 241.3 PE(O-16:0/20:4) 5.48 724.5 303.2 PE(O-16:0/22:6) 5.38 748.5 327.2 PE(O-18:0/20:4) 5.97 752.6 303.2 PE(O-18:0/22:6) 5.87 776.6 327.2 PE(P-16:0/20:4) 5.48 722.6 303.3 PE(P-16:0/20:5) 5.11 720.6 301.3 PE(P-16:0/22:4) 5.83 750.6 331.3 PE(P-16:0/22:6) 5.29 746.6 327.3 PE(P-18:0/18:1) 6.4 728.6 281.3 PE(P-18:0/18:2) 6.08 726.6 279.2 PE(P-18:0/20:4) 5.96 750.6 303.3 PE(P-18:0/20:5) 5.61 748.6 301.3 PE(P-18:0/22:6) 5.79 774.6 327.3 PE(P-18:1/20:4) 5.48 748.5 303.3 PE(P-18:1/22:6) 5.29 772.5 327.3 PEth(16:0_18:1) 5.4 772.5 255.1 PEth(18:1/18:1) 5.4 773.6 281.2 PG(15:0/18:1(d7)) 4.87 740.6 241.3 PG(16:0_18:1) 5.13 747.5 255.3 PG(16:0_20:4) 4.61 769.5 255.3 PG(16:0_22:6) 4.28 795.5 255.3 PG(18:0_18:1) 5.6 775.5 281.3 PG(18:0_20:4) 5.14 797.5 283.3 PG(18:0_22:6) 4.79 823.5 283.3 PG(18:1/18:1) 5.14 773.4 281.4 PI(15:0/18:1(d7)) 4.87 828.6 241.3 PI(16:0_18:1) 5.04 835.6 255.3 PI(16:0_20:4) 4.61 857.6 255.3 PI(16:0_22:6) 4.43 881.6 255.3 PI(18:0_18:1) 5.51 863.6 283.3 PI(18:0_20:4) 5.12 885.6 283.3 PI(18:0_22:6) 4.97 909.6 283.3 PI(18:1/18:1) 5.04 861.6 281.3 PI(20:4/20:4) 3.96 905.6 303.3 PS(15:0/18:1(d7)) 4.94 753.6 241.3 PS(16:0_18:1) 5.19 760.6 255.3 PS(16:0_20:4) 4.68 782.6 255.3 PS(16:0_22:6) 4.5 806.6 255.3 PS(18:0_18:1) 5.66 788.6 283.3 PS(18:0_20:4) 5.25 810.6 283.3 PS(18:0_22:6) 5.02 834.6 283.3 PS(18:1/18:1) 5.19 786.6 281.3 PS(22:6/22:6) 3.66 878.5 327.3 Stearic acid 3.6 283.2 283.2 PE(P-18:0/18:1(d9)) 6.4 737.6 290.2 METABOLITES_END #END